University of Zurich

Mydecine, JHU Expand Pact Focused Initially On Smoking Cessation Mydecine Innovations Group Inc. and Johns Hopkins University said on 18 August that they will undertake a five-year collaboration t

Synthorx Inc. is putting its Expanded Genetic Alphabet platform to test in the company's first-ever clinical trial, evaluating the recombinant interleukin-2 (IL-2) THOR-707 in patients with advanced

The motto in venture capital investment for biopharmaceutical companies these days seems to be "go big or go home," with $100m-plus financings – often at the Series A stage – becoming more frequent an

In the cardiovascular device arena, as in so many other medical device fields, success tends to come only after halting progress. In coronary artery disease, for example, an interventional revolution